Objective: Charcot-Marie-Tooth type 4J (CMT4J) is a rare autosomal recessive neuropathy caused by mutations in FIG4 that result in loss of FIG4 protein. This study investigates the natural history and mechanisms of segmental demyelination in CMT4J. Methods: Over the past 9 years, we have enrolled and studied a cohort of 12 CMT4J patients, including 6 novel FIG4 mutations. We evaluated these patients and related mouse models using morphological, electrophysiological, and biochemical approaches. Results: We found sensory motor demyelinating polyneuropathy consistently in all patients. This underlying myelin pathology was associated with nonuniform slowing of conduction velocities, conduction block, and temporal dispersion on nerve conduction studies, which resemble those features in acquired demyelinating peripheral nerve diseases. Segmental demyelination was also confirmed in mice without Peripheral neuropathies resulting from genetic mutations often affect myelination during development, called dysmyelination, as seen in Charcot-Marie-Tooth type 1A (CMT1A) caused by PMP22 duplication. CMT1A dysmyelination 1 causes shortened internodes and uniform slowing of conduction velocity (CV), which
denotes slowed CV with minimal variations between different nerves in an affected patient. 2 In contrast, the slowing of CV in patients with acquired demyelinating diseases is nonuniform and often coexistent with temporal dispersion and/or conduction block. Pathologically, nerve fibers demonstrate removal of myelin in a portion of internodes and normal myelin in other internodes, called segmental demyelination. 3 Demyelination is the primary pathology in a long list of neurological disorders, including chronic inflammatory demyelinating polyneuropathy and GuillainBarr e syndrome. Despite the increasing treatment options (predominantly immunomodulatory), disabilities still develop in patients with demyelinating diseases. This is largely due to a general lack of understanding of the molecular mechanisms that regulate demyelination.
FIG4 is a phosphatase with specificity toward the 5 0 -phosphate in phosphatidylinositol-3,5-disphosphate (PI3,5P 2 ), which plays an important role in regulating lysosomal membrane trafficking. Although FIG4 can decrease PI3,5P 2 levels via its phosphatase action, it can also promote PI3,5P 2 synthesis by acting as a secondary scaffold. FIG4 (SAC3) complexes with Vac14 (ArPIKfyve in mammalian cells), which then interacts with and activates the 5 0 -kinase of PI3P known as Fab1 (PIKfyve). 4, 5 This PAS complex mediates the conversion of PI3P to PI3,5P 2 11 Lysosomal membrane trafficking has been suggested to be important for myelination. 12, 13 In this study, we studied 12 patients with CMT4J enrolled over the past 9 years, as well as relevant mouse models. Unlike certain subtypes of CMT1 with uniform slowing of CV, nonuniform slowing with temporal dispersion and conduction block was found in patients with CMT4J. Similar nerve conduction changes were observed in FIG4-deficient mice correlating with removal of internodal myelin and macrophage increase in spinal roots. These features recapitulate those seen in acquired demyelinating diseases, indicating that understanding FIG4 deficiency may reveal novel molecular pathways that alter lysosomal functions common to both genetic and acquired forms of demyelination.
Subjects and Methods

Patients
Twelve patients have been prospectively evaluated (by J.L. or M.E.S.) at Vanderbilt Medical Center or University of Iowa. Note that Cases 2, 9, and 10 have been published before. 14, 15 New data on these 3 cases were included here. This study was approved by the institutional review board of both institutions. Written consents/assents were obtained from all participants.
CMT Examination Score (CMTES; v2) 16 was obtained for most patients (listed in Table 1 ). CMTES ranges from 0 to 28, with higher scores indicating increased disease severity.
Nerve Conduction Studies
Nerve conduction study (NCS) data in humans were acquired using conventional methods. 17 Conduction block was defined as 50% reduction of compound muscle action potential (CMAP) evoked by proximal stimulation. 18 Temporal dispersion was defined as dissynchronized CMAP with 2 or more extra phases and 30% increase of negative peak duration. Mouse NCSs have been described previously.
19
DNA Sequencing
Patient DNA was evaluated by targeted gene-panel next generation sequencing, a service provided by Medical Neurogenetics (Atlanta, GA), GeneDx (Gaithersburg, MD), Invitae (San Francisco, CA), or Athena Diagnostics (Worcester, MA). Specific mutations in FIG4 were verified by Sanger sequencing.
Primary Human Fibroblast Culture and Lysosomal Fission Assay
Primary human fibroblast culture was described previously. 20 Lysosomal fission was tested as described previously. 11 Fibroblasts in culture were treated with vehicle or vacuolin-1 (5 mM, Cat# 673000, Sigma, St Louis, MO) for 1.5 hours to increase lysosome size, and cells were imaged. After removal of vacuolin-1, cells were allowed to recover their lysosomal sizes through fission. At the end of the 8th hour after washing out, cells were imaged again. Percentages of cells with vacuoles 3 mM in diameter were counted.
RNA Extraction and Real-Time Polymerase Chain Reaction for Exon Skipping Analysis
Total RNA was isolated from the fibroblasts using Trizol reagents. Reverse transcription was performed in 1 mg RNA using random hexamer primer mixture (Cat# 04379012001, Roche, Basel, Switzerland). FIG4 cDNA was amplified using the following primers: for the 451bp product, forward, 5 0 -GGACACCAGAGGTGATAAAG-3 0 and reverse, 
Western Blot
Proteins from fibroblasts were extracted using radioimmunoprecipitation assay buffer with proteinase/phosphatase inhibiter cocktail (Cat# 5872, Cell Signaling Technology, Danvers, MA). Samples were loaded into sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels, transferred to polyvinylidene difluoride membrane, and blotted with primary antibodies, followed by secondary antibodies. The immune complexes were detected by the chemiluminescence.
Animal Models
Pale tremor (plt 5 Fig4
) mouse from Jackson Laboratory (Bar Harbor, ME) was a spontaneously occurring mutant following insertion of a Fig4 disrupting transposon, which blocked its expression. 8 This mouse was backcrossed with C57B6 over 9
generations to reach congenic background. Design and production of Figure 6A . We crossed Fig4 f/f mice with myelin protein zero-cre (Mpz cre ) mice (Jackson Laboratory, stock # 017927) to produce Schwann cell-specific knockout (scFig4 2/2 ) mice. We produced the neuron-specific knockouts (nFig4 2/2 ) by crossing
Fig4
f/f mice with neuron-specific synapsin-cre mice (Syn Cre ; Jackson Laboratory, stock # 003966). All mice were on the C57B6 background.
Teased Nerve Fiber Preparation, Paraffin Embedding, and Immunofluorescence Staining
Teased nerve fiber analysis was described previously. 21 In brief, nerves were fixed in 4% paraformaldehyde for 30 minutes to 16 hours (depending on primary antibodies used). Sciatic nerves were teased into individual fibers on glass slides. Slides were dried overnight, reacted with primary antibodies, and then incubated for 1.5 hours with secondary antibodies. Slides were examined under a fluorescent microscope (DM6000B, Leica Microsystems, Wetzlar, Germany). Paraffin sections were prepared according to previously published methods. 22 They were stained with a procedure similar to that above.
Antibodies
The following antibodies were from Cell Signaling Technology 
Semithin Section and Internodal Length Quantification
These techniques have been described previously. 14 The semithin sections were stained with toluidine blue and examined by light microscopy. The 9mm nerve segment in liquid Epon was teased into individual nerve fibers for imaging. The internodal length was measured by software (Leica 6000B).
Morphometric Analysis
Five images were captured across the entire area of each sciatic nerve transverse section under a 3100 lens through a Leica 23 was used to automatically label the myelin on the images, producing a mask image with minimal manual intervention. ImageJ (1.51n) was used to split the resulting mask image into two: one for inner ellipses of the myelin sheath and the other for outer ellipses. ImageJ's built-in "measure particles" command was used to measure the area of each ellipse and its position on the image. Axon density, myelin thickness, and g ratio were calculated from these measurements.
Statistics
For comparison of internodal length between wild-type (wt) and ), and random Animal effects. The random effects were included to account , and 6 were analyzed for their lysosomal fission as described in Subjects and Methods. The cells were exposed to vacuolin-1 for 1.5 hours and imaged, followed by washing with culture media. The cells were imaged again at the 8th hour after the washout. Percentages of cells with lysosomal vacuoles 3 mM in diameter were counted in the images. *Statistically significant with p < 0.05.
for correlations between lengths on the same animal. Because both fixed and random effects were included, this model was a mixed effects model. To compare CV or CMAP in different groups (eg, wt vs Fig4 2/2 ), a nonparametric Wilcoxon rank sum test was used.
Results
Natural History in Patients with CMT4J Demonstrates Sensory Motor Demyelinating Polyneuropathy That Recapitulates Features in Acquired Demyelinating Diseases
CLINICAL PHENOTYPES. Phenotypic details are listed in Table 1 . The 12 patients were separable into 3 groups based on their ages of symptom onset: early onset (n 5 3) with severe limb paralysis on the initial visit, teenage onset with mild to severe limb weakness on their 1st visit (n 5 7), and adult onset (n 5 2) with mild weakness on their 1st visit. Onset was defined as the age at which medical attention was first sought for a related major neurological symptom. This definition disregarded subtle complaints such as fatigue, mild foot deformities, occasional tripping, and ankle twisting, which may be present in all patients, but onset was difficult to recall. A case of CMT4J is described below as an example.
Case 1 (Teenage Onset). This is a 17-year-old boy who met all developmental milestones. His mother noticed his feet slapping on the ground when walking at 12 years of age. He sprained his ankles many times. Over the previous 2 years, he had started to buckle his knees and fall, which prompted the initial neurological evaluation. He denied any sensory disturbance. He has excelled academically. On neurological examination, he had hammer toes with high-arched feet. His muscle strength was 4 in distal but 5 in proximal muscles of limbs. He had decreased pinprick, touch, and vibration sensation in his feet. Deep tendon reflexes were absent.
RARE PHENOTYPES: CENTRAL NERVOUS SYSTEM INVOLVEMENT AND/OR RAPIDLY PROGRESSIVE
IRREVERSIBLE ASYMMETRIC WEAKNESS. Nine of the 12 patients showed no obvious central nervous system (CNS) symptoms. Brain magnetic resonance imaging (MRI) data in 2 of the 9 patients showed no abnormality. Cases 4 and 5 in the early onset group developed mental retardation with brain white matter changes visualized on MRI (see Table 1 , Fig 1A) . However, both cases possessed another mutation: trisomy of chromosome 21 in Case 4 and glycerol kinase deficiency (exon 19 deletion in GK gene on Xp21.2) in Case 5. Case 2 in the teenage onset group presented with Parkinson-like symptoms in addition to polyneuropathy. 24 DNA testing for whole chromosomes was not done. Despite CNS symptoms, demyelinating polyneuropathy in NCSs was still present in the 3 cases. Case 5 had a sural nerve biopsy showing thinly myelinated nerve fibers with severe loss of large myelinated axons (see Fig  1C, D) . Therefore, CNS symptoms are uncommon among patients with CMT4J. In cases with conspicuous CNS abnormalities, second genetic mutations should be sought. Minor trauma has been associated with rapidly progressive asymmetric weakness in Case 10 (amyotrophic lateral sclerosis [ALS]-like phenotype), which was irreversible until her death.
14 Furthermore, genetic studies in 2 large cohorts of patients with ALS have revealed some FIG4 variants as genetic risk factors but not causal for the disease. 25, 26 In the present cohort, none had the phenotype of rapidly progressive asymmetric weakness, including 4 patients (Cases 3, 6, 7, 8) who had a fall or surgeries but did not develop any rapid progression of weakness after trauma. Case 12 developed asymmetric weakness in the left leg, but it was chronic and slowly progressive. Case 6 developed a transient exacerbation of weakness during pregnancy but stabilized after intravenous immunoglobulin treatment (see Table 1 ). Table 2 show a highly consistent pattern of sensory motor demyelinating polyneuropathy in all cases, with several striking features:
1. Unlike CMT1A patients, in whom there is uniform slowing of CV, 3 patients with CMT4J showed nonuniform slowing of CV. For instance, Case 3 showed a CV of 29m/s in the left median nerve and 39m/s in the left ulnar nerve. Nine cases had conduction block. 27 Conduction block was difficult to assess in 3 pediatric cases because submaximal stimulations may be used in children. Of 6 cases with CMAP waveforms available for review, 3 showed temporal dispersion (see Fig 1B) . 2. Because some nerves had CV < 10m/s, the decreases of CVs were too severe to be a secondary change from axonal loss (see Table 2 ). These observations support a primary rather than secondary demyelinating process. 3. Of 8 patients who had needle electromyography, 6 showed fibrillations, positive waves, and reduced recruitment of motor unit action potentials indicative of axonal degeneration (see Table 2 ).
Taken together, a consistent phenotype in patients with CMT4J is sensory motor demyelinating polyneuropathy with features recapitulating acquired demyelinating polyneuropathies. This NCS feature is also in line with the pathological findings in sural nerve biopsies shown in Figure 1C and a 60% de-/remyelination in teased nerve fiber preparation previously reported. 14 
Mutations in All CMT4J Patients Resulted in Loss of Function of FIG4
Mutations in all 12 cases (see Table 1 ) were evaluated by 2 servers: PolyPhen-2 28 and SIFT. 29 Both PolyPhen-2
and SIFT predicted that all identified FIG4 mutations were pathogenic. To further substantiate the pathogenicity, we performed Western blot on protein lysates extracted from fibroblasts cultured from all patients' skin biopsies. FIG4 proteins were either absent or severely reduced when blotted by anti-FIG4 antibodies (Fig 2A) . Cases 2 and 5 had intronic mutations (see Table 1 ). We performed PCR on cDNA isolated from their fibroblasts with primers flanking the intronic mutations. In Case 2, we identified a shortened band in addition to the normal allelic band, confirming the previous report (see Fig 2) . 15 The shortened band was cut and sequenced, which showed a deletion of exon 18, thereby demonstrating abnormal splicing due to the intronic mutation. In Case 5, a deletion of exon 22 by abnormal splicing was identified.
Interestingly, Case 3, with normal strength, had a FIG4 protein level that was about 4 times higher than those in the other 11 patients (see Fig 2A) . The levels of FIG4 were not significantly different between early and teenage onset groups (0.05 6 0.02 vs 0.05 6 0.03, p > 0.05; these numbers were relative values over loading control).
Case 12 had homozygous mutations of I41T. I41T mutation has been shown to destabilize FIG4, leading to a rapid degradation of FIG4 by proteasomes in in vitro studies. 30 I41T mutation has been hypothesized to produce some functional FIG4 proteins that would moderate the disease. 31 This hypothesis was tested here; the FIG4 level in this case was comparable to other cases in the group with teenage onset. This finding suggests that any compensation effect from I41T would be minimal.
Our previous study has shown that abnormal lysosomal storage in FIG4-deficient mouse fibroblasts was mainly caused by a lysosomal fission defect, whereas lysosomal fusion was normal. 11 We verified this mechanism in 5 patients with CMT4J. After lysosomes were enlarged by application of vacuolin-1 (5 mM), lysosomal sizes gradually decreased via fission. This recovery was found to be highly abnormal in 4 cases (early onset 1 teenage onset). As expected, the recovery in Case 3 (adult onset with high level of FIG4 and normal strength) was close to that in normal controls (see Fig 2F) . Together, these findings support the loss of function of FIG4 in all 12 cases, including 6 cases with novel pathogenic mutations. The FIG4 deficiency also resulted in lysosomal fission defect in human cells. Fig 3C-F) .
Segmental Demyelination Was Found in Sciatic
Shortened internodes mainly affected large-diameter fibers rather than small-diameter fibers (see Fig 3E) . (Fig 4) . In teased nerve fiber preparation, the Schwann cell nuclei that stained positively for c-Jun were consistently correlated with segmental demyelination. The increase of nuclear c-Jun was found even in partially demyelinated internodes. Next, we quantified a battery of dedifferentiation factors using Western blot (Fig 5A, B) . c-Jun, phosphorylated c-Jun (pc-Jun), and p75 were robustly increased in ). At postnatal day 21, sciatic nerves were dissected for Western blot with antibodies against FIG4. Note that non-Schwann cells would still express some FIG4 in scFig4 2/2 nerves. We stripped epineurium of sciatic nerves. This procedure resulted in a low concentration of total proteins. Nevertheless, FIG4 was readily detectable in roots under electron microscopy in our previous study. 14 We quantified macrophages in P21 mice by staining nerves with macrophage-specific CD68 antibodies (see Fig 5G) . There was a robust increase of macrophages in These observations strongly suggest that segmental demyelination resulted from contributions of multiple cell types. Successful therapy would not be achieved by targeting a single cell population but would require systemic delivery. BAPTA-AM has been used systemically (intraperitoneally) in mice. 34 BAPTA suppressed c-Jun levels in Fig4 2/2 mouse sciatic nerves as shown in Figure   5 . Therefore, for proof of concept, we performed a trial of systemic BAPTA delivery in Fig4 2/2 mice (subcutaneous injection). Due to potential toxicity, a low dose (5mg/kg, concentration 5 0.5mg/ml) was used. Based on the variability of segmental demyelination counted on teased nerve fibers, our power calculation showed 5 mice (at P21 of age) per group would allow an 86% chance to detect a significant difference. Five mice were randomized into 3 groups, treated with BAPTA, vehicle (dimethylsulfoxide [DMSO]), and saline (to exclude effect from DMSO). Outcome measurement was done by experimenters who were blinded to the treatment groups.
Schwann Cells in
There was a significant reduction of demyelinated nerve fibers in the BAPTA-treated group in comparison with the DMSO and saline groups (saline 11.9 6 1.0% vs DMSO 8.7 6 2.4% vs BAPTA 5.2 6 1.6%, p < 0.05).
Discussion
CMT4J is an ultrarare disease, and 12 patients with this genetic condition constitute a large cohort. Phenotypic analysis shows that segmental demyelination is a highly consistent feature. These findings strongly indicate a critical dependence of FIG4 for the normal functions of peripheral nerve myelin. This is consistent with the highlevel expression of FIG4 in Schwann cells. 22 The natural history of our patients disputes 2 previous speculations. First, CNS phenotypes in a subset of patients with CMT4J are suspected to relate to more severe depletion of FIG4. 31 However, patients with early onset and severe CNS abnormalities (Cases 4 and 5) had levels of FIG4 similar to those of patients with teenage onset (see Fig 2) . Instead, second mutations were found in the 2 cases with early onset. Because there are only 2 cases here, a causal relationship still cannot be established between CNS abnormalities and the 2nd mutations. However, the two 2nd mutations have been associated with neurological phenotypes. After all, it is well known that phenotypic variations in monogenic diseases can be caused by additional genetic modifiers. 35 Another speculation was that minor trauma triggers acceleration of disease progression. 14 However, surgeries in 4 patients and trauma in 1 case did not result in rapid disease progression. Instead, a majority of our CMT4J patients presented with relatively symmetric distal > proximal weakness and sensory deficits in limbs. In addition, although all CMT4J mutations resulted in FIG4 deficiency, the levels of FIG4 could not differentiate patients with early onset from those with teenage onset. Thus, other intrinsic and extrinsic factors (not necessarily trauma) may have been involved in the modification of CMT4J phenotype. We believe that the consistent pathology of segmental demyelination in CMT4J is highly significant for the following reasons. First, demyelination in patients with CMT4J and Fig4 2/2 mouse models recapitulates many features typically seen in acquired demyelinating peripheral nerve disorders, including conduction block, temporal dispersion, nonuniform slowing on NCS, and macrophage increase in areas with weak blood-nerve barrier. The demyelination appears to be primary. For instance, in Cases 9 and 10, most motor nerves in arms had normal amplitudes of CMAP, but conduction velocities were still very much decreased (see Table 2 ). Some acquired demyelinating features have also been reported in a subset of patients with CMTX1 36 and a heterozygous myelin protein zero knockout mouse (Mpz
). 37 Thus, studies of these diseases may reveal novel molecular pathways potentially relevant to many demyelinating diseases. There have been many precedent examples showing that acquired or sporadic diseases can be studied by utilizing genetic models derived from inherited disorders. In the field of ALS, a variety of rodent genetic models, such as the C9ORF72, SOD1, and TDP43 transgenic mice, have been used to study the pathogenic mechanisms of the disease. Although ALS patients with mutations in C9ORF72, SOD1, or TDP43 are rare, investigations using these genetically manipulated animals have made remarkable contributions to our understanding of the pathogenesis of ALS in general. 38, 39 delivery to reach multiple cell populations is required. This notion is also in line with previous observations that excessive lysosomal storage was found in multiple cell types and organs (peripheral nerves, oligodendrocytes, CNS neurons, spinal motor neurons, dorsal root ganglia neurons, skin fibroblasts, spleen cells), 9, 14 40 In line with this idea, axonal damage has been shown to increase intracellular Ca 21 level in myelin. 42 It is also interesting to note that depletion of macrophages by the treatment of CSF1R receptor inhibitor improved pathology in 2 inherited neuropathy mouse models. 43 It should be clarified that our findings do not exclude developmental abnormality of myelin (dysmyelination) in CMT4J. For instance, we observed shortened internodes in Fig4 2/2 mice (see Fig 3) . Fig 6) , suggesting that abnormal signals from FIG4-deficient Schwann cells instruct wt axons to degenerate. Although not a focus of the present study, it would be of neurobiological significance to unveil any such abnormal signals. In summary, our study strongly supports a critical role of FIG4 in peripheral nerve myelin. Our observation enables us to propose a mechanistic model (see Fig 7) to be further tested. Although our previous study has shown an increase of intracellular Ca 21 
